在HBeAg阴性的慢性乙型肝炎中停止核苷类似物治疗

StephenW

Stopping Nucleos(t)ide Analogue Therapy in HBeAg-negative Chronic Hepatitis B
Yun-Fan Liaw  1
Affiliations

    PMID: 32433984 DOI: 10.1053/j.gastro.2020.01.056
To the Editor: The recent article in Gastroenterology by Liem et al [1] addressed a current hot issues of finite nucleos(t)ide analogue (Nuc) therapy in chronic hepatitis B. This review on challenges with stopping Nuc therapy comes timely and is generally sound. However, several points related to hepatitis B e antigen (HBeAg)-negative patients, especially on hepatitis B surface antigen (HBsAg) loss rate and safety require clarification and further discussion.
在HBeAg阴性的慢性乙型肝炎中停止核苷类似物治疗
廖云凡1
隶属关系

     PMID：32433984 DOI：10.1053 / j.gastro.2020.01.056
致编辑：Liem等人[1]最近在胃肠病学杂志上发表的文章解决了慢性乙型肝炎中有限核苷酸类似物（Nuc）治疗的当前热点问题。有关停止Nuc治疗的挑战的评论是及时的，并且是 一般声音。 但是，与乙型肝炎e抗原（HBeAg）阴性患者有关的几点，特别是与乙型肝炎表面抗原（HBsAg）的丢失率和安全性有关，需要澄清和进一步讨论。

https://www.gastrojournal.org/article/S0016-5085(20)30672-7/pdf